British Journal of Haematology

Article	Citations
Myeloma patients with COVID‐19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine	119
B‐cell lymphoma mimicking relapsing polychondritis	103
Lower anti‐spike levels in B‐cell‐depleted patients after convalescent plasma transfusion suggest the need for repeated doses	99
Cell erythroid maturation approach: a new paradigm in the road map towards a cure for β‐thalassaemia syndromes	93
Challenges and solutions to superior chimeric antigen receptor‐T design and deployment for B‐cell lymphomas	89
Positron emission tomography derived metrics in relapsed or refractory large B‐cell lymphoma with residual disease before autologous stem cell transplant	81
Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis	75
Clinicopathological characteristics and long‐term outcomes of plasmablastic lymphoma in British Columbia	74
Exome sequencing in high and low fetal haemoglobin Arab–Indian haplotype sickle cell disease	65
What complements complement in transplant‐associated thrombotic microangiopathy?	62
Safety and efficacy of a Hb‐triggered single‐unit red cell transfusion policy for haemato‐oncological inpatients	60
	59
Cancer‐associated venous thrombosis in adults (second edition): A British Society for Haematology Guideline	57
Whole‐blood transcriptome analysis reveals distinct gene expression signatures in paediatric patients with sickle cell anaemia before and after exercise	57
Asparagine transport through SLC1A5/ASCT2 and SLC38A5/SNAT5 is essential for BCP‐ALL cell survival and a potential therapeutic targ	56
Age, GVHD prophylaxis, and timing matter in thrombotic microangiopathy after haematopoietic cell transplantation—A secondary CIBMTR analysis	55
MN1::ETV6‐positive de novo T‐cell acute lymphoblastic leukaemia is sensitive to venetoclax: A case report	53
Clinical perspectives on post‐induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantation	52
Burden of vaso‐occlusive crisis, its management and impact on quality of life of Indian sickle cell disease patients	52
Conditional survival of younger patients with mantle cell lymphoma: Results from a randomized phase III trial of the European MCL Network	50
Long‐term outcomes of avascular necrosis in sickle cell disease using joint‐specific patient‐reported outcome measures: Results from a multicentre study	49
Issue Information	49
JAK2 is a critical therapeutic target in VEXAS syndrome treated with ruxolitinib	46
Identification and management of preoperative anaemia in adults: A British Society for Haematology Guideline update	45
Prevalence of kidney health genetic variants in adults with sickle cell nephropathy	44

Difficult‐to‐treat primary immune thrombocytopenia in adults: Prevalence and burden. Results from the CARMEN‐France registry	44
Delta‐globin gene expression improves sickle cell disease in a humanised mouse model	44
Real‐world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: Results from the TRAIT study	44
Erythrocyte type 1 equilibrative nucleoside transporter expression in sickle cell disease and sickle cell trait	43
The 12‐week kinetics of anti‐SARS‐CoV‐2 antibodies in different haematological cancers after vaccination with BNT162b2	41
Risk of recurrent venous thromboembolism in patients with autoimmune diseases: data from the Registro Informatizado de Enfermedad TromboEmbólica (RIETE) registry	41
Low levels of minimal residual disease after induction chemotherapy for BCR‐ABL1‐negative acute lymphoblastic leukaemia in adults are clinically relevant	40
Allogeneic haematopoietic cell transplantation for myelofibrosis: a real‐life perspective	39
Pathogenesis, risk factors and therapeutic options for autoimmune haemolytic anaemia in the post‐transplant setting	39
Van der WaltJ., OraziA., ArberD. A. (editors) Diagnostic Bone Marrow HaematopathologyCambridge, UK: Cambridge University Press, 2021. ISBN 978‐1‐107‐14 500‐9.	38
Transient increase in platelet counts associated with COVID‐19 infection during TPO‐RA as the second‐line treatment in children with ITP	38
A UK consensus algorithm for early treatment modification in newly diagnosed systemic light‐chain amyloidosis	38
Issue Information	37
Adjunctive viral cell culture supports treatment decision‐making in patients with secondary humoral immunodeficiency and persistent SARS‐CoV‐2 infection	37
Lenalidomide in combination with R‐ESHAP in patients with relapsed or refractory diffuse large B‐cell lymphoma: A phase 2 study from GELTAMO	36
Graham Serjeant, Sickle Cell, Jamaica and Beyond: A Life, Ian Randle Publishers (Kingston and Miami), 2021	36
Omacetaxine added to a standard acute myeloid leukaemia chemotherapy regimen reduces cellular FLIP levels, markedly increasing the incidence of eccrine hidradenitis	36
Bone marrow pseudo‐Gaucher cells demonstrating haemophagocytosis associated with extranodal NK/T cell lymphoma, nasal type	35
High risk of relapse with intermediate dose cytarabine for consolidation in young favourable‐risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis an	34
The impact of clonal diversity and mosaicism on haematopoietic function in Fanconi anaemia	34
A sinister case of pseudothrombocytosis	34
Issue Information	34
Rivaroxaban for the treatment of superficial vein thrombosis, experience at King’s College Hospital	33
An inherited gain‐of‐function risk allele in EPOR predisposes to familial JAK2V617F myeloproliferative neoplasms	32
Management of luspatercept therapy in patients with transfusion‐dependent β‐thalassaemia	32
Macrothrombocytopenia and stomatocytosis in sitosterolaemia	32
Childhood aggressive B‐cell non‐Hodgkin lymphoma in low–middle‐income countries	32
Haploidentical haematopoietic stem cell transplantation for TP53‐mutated acute myeloid leukaemia	31
Diagnostic value of multigene sequencing for inherited thrombocytopenia	31
Obinutuzumab as consolidation after chemo‐immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial	30
Issue Information	30
Accelerated death of megakaryocytes from Wiskott–Aldrich syndrome patients	30
In vivo 18F‐fluoride‐PET imaging reveals pronounced heterogeneity in bone formation in multiple myeloma patients	29
Can circulating CD34+ cell count be used for the prognosis of myelofibrosis?	29
The significance of mixed chimaerism and cell lineage chimaerism monitoring in paediatric patients post haematopoietic stem cell transplant	28
Refining risk stratification in paediatric B‐acute lymphoblastic leukaemia: Combining IKZF1plus and Day 15 MRD positivity	28
The role of genetics in refractory immune thrombocytopenia	28
Patient preferences in the treatment of stage III/IV classic Hodgkin lymphoma: Results from the CONNECT cross‐sectional survey	28
Inherited cancer predisposing mutations in patients with therapy‐related myeloid neoplasms	28
Correctly marking the 70th anniversary of Castleman disease—Response	28
Venetoclax and hypomethylating agents in critically ill patients with newly diagnosed acute myeloid leukaemia	27
Clinical factors for central nervous system progression and survival in primary vitreoretinal lymphoma	26
Emicizumab prophylaxis in infants: Single‐centre experience	26
Issue Information	25
Finding the best haematopoietic stem cell transplant regimen for GATA2 haploinsufficiency: how close are we?	24
	24
The impact of surveillance imaging after curative‐intent radiotherapy for limited‐stage follicular lymphoma	24
In situ follicular neoplasia with translocation of BCL6 – a new variant with different immunohistochemical properties	24
Case series: CYP Inhibition and low dose ibrutinib for steroid‐refractory chronic graft‐versus‐host disease	24
Hepatic haemophagocytosis in haematology patients with hepatic dysfunction: prognostic impact and contribution of liver biopsy combined with the haemophagocytic syndrome diagnostic score (HScore)	23

	23
Haematopoietic stem cell mobilisation followed by high‐dose chemotherapy and autologous stem cell transplantation for patients with sickle cell disease and myeloma	23
Issue Information	23
What does the term ‘sickle cell disease’ mean?	22
Mortality trends of chronic lymphocytic leukaemia in the United States with the emergence of targeted therapy	22
Immune thrombocytopenia after immune checkpoint inhibitor therapy	22
CAR‐T cell therapy is superior to standard of care as second‐line therapy for large B‐cell lymphoma: A systematic review and meta‐analysis	22
How I manage myeloproliferative neoplasm‐unclassifiable: Practical approaches for 2022 and beyond	22
Vaccine‐induced immune thrombocytopenia and thrombosis: The decline in anti‐platelet factor 4 antibodies is assay‐dependent	22
Issue Information	21
Issue Information	21
Immunogenicity and clinical effectiveness of mRNA vaccine booster against SARS‐CoV‐2 Omicron in patients with haematological malignancies: A national prospective cohort study	21
Prolonged platelet hyperactivity after COVID‐19 infection	21
COVID‐19 vaccine response in chronic lymphocytic leukaemia is more than just seroconversion	21
Increasing insight in the value of repetitive COVID‐19 vaccination in patients with haematological malignancies in the Omicron era	21
Novel identification of t(14;18)(q32;q21)/IGH::MALT1 in chronic lymphocytic leukaemia	21
Oxygen gradient ektacytometry does not predict pain in children with sickle cell anaemia	21
Impact of community health workers on quality of life in adolescents and young adults with sickle cell disease: The SHIP‐HU study	21
R‐CHOP treatment for patients with advanced follicular lymphoma: Over 15‐year follow‐up of JCOG0203	20
Daratumumab for refractory immune‐mediated thrombotic thrombocytopenic purpura	20
Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia	20
Issue Information	20
Clinico‐biological features, treatment and prognosis of primary myeloid sarcoma: A French retrospective multi‐centric observational study	20
Immune response and adverse events after vaccination against SARS‐CoV‐2 in adult patients with transfusion‐dependent thalassaemia	20
Body size and risk of non‐Hodgkin lymphoma by subtype: A pooled analysis from six prospective cohorts in the United States	20
Immune‐mediated thrombocytopenia and IL‐6‐mediated thrombocytosis observed in idiopathic multicentric Castleman disease	20
Secondary primary malignancies after CD‐19 directed CAR‐T‐cell therapy in lymphomas: A report from the Italian CART‐SIE study	20
The impact of COVID‐19 vaccination on patients with a history of heparin‐induced thrombocytopenia	19
Clinical significance of the immunoglobulin G heavy‐chain repertoire in peripheral blood mononuclear cells of adult T‐cell leukaemia–lymphoma patients receiving mogamulizumab	19
A novel ATRX variant with splicing consequences in myelodysplastic syndrome with acquired alpha thalassaemia	19
Issue Information	19
Intra‐ and extracellular crystal deposition in a case of amyloid light chain amyloidosis	19
Spontaneous splenic rupture as initial presentation of diffuse large B‐cell lymphoma	19
Paediatric ambiguous lineage leukaemia with monocytic differentiation at diagnosis: case series and review of literature	19
The Frontiers of Plasma Cell Neoplasms JiFeng Yu and Peter Y. Z. Jiang (editors) Amazon.com direct publishing, USA, 2021 (ISBN: 9798589451924).	19
Novel RASGRP2 variants in platelet function defects: Indian study	19
	19
Comprehensive proteomic analysis reveals dynamic phospho‐profiling in human early erythropoiesis	19
Issue Information	18
A British view on the management of Waldenström macroglobulinemia	18
Cup‐shaped nuclei in acute promyelocytic leukaemia	18
Complete responses to odronextamab in two patients with diffuse large B‐cell lymphoma refractory to chimeric antigen receptor T‐cell therapy	18
Issue Information	18
Radiological evidence of resolution of fatty marrow after bone marrow transplantation	18
Differentiation therapy using low‐dose venetoclax in a variant acute promyelocytic leukaemia carrying ZBTB16‐RARA	18
Alternative donor transplantation for severe aplastic anaemia in 2021: haplo donor, cord blood or both?	17
Puumala virus‐induced lymphocyte anomalies	17
A novel MYC–non‐IG fusion in refractory diffuse large B‐cell lymphoma	17
SOCS3 deregulation contributes to aberrant activation of the JAK/STAT pathway in precursor T‐cell neoplasms	17
Giant pelvic haemophilic pseudotumor	17
How to dose and monitor argatroban for treatment of HIT	17
Hydroxyurea therapy decreases coagulation and endothelial activation in sickle cell disease: a Longitudinal Study	17
Comparative study of therapy‐related and de novo adult b‐cell acute lymphoblastic leukaemia	17
β‐Thalassemia in childhood: Current state of health in a high‐income country	17
Issue Information	17
Rare and fatal complication of immune checkpoint inhibition: a case report of haemophagocytic lymphohistiocytosis with severe lichenoid dermatitis	17
COSMIC, chemotherapy plus ofatumumab at standard or mega‐dose in chronic lymphocytic leukaemia, a phase II randomised study	17
The clinical course of COVID‐19 in pregnant versus non‐pregnant women requiring hospitalisation: results from the multicentre UK CA‐COVID‐19 study	17
Intraoperative cell salvage using swab wash and serial thromboelastography in elective abdominal aortic aneurysm surgery involving massive blood loss	17
AML in the elderly—A global view	16
Autologous stem cell transplantation in the age of ANDROMEDA	16
Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline	16
Transfusion Medicine: Case studies and Clinical Management, Second EditionBy AleksandarMijovic, Springer Nature Switzerland. 2023. pp. 1–155. ISBN: 978‐3‐031‐31461‐2	16
A novel gain‐of‐function PIP4K2A mutation elevates the expression of β‐globin and aggravates the severity of α‐thalassemia	16
In vitro assessment of the sensitivity to APR‐246 + azacitidine combination predicts response to this combination in myelodysplastic/acute myeloid leukaemia patients	16
Parameters of long‐term response with CD28‐based CD19 chimaeric antigen receptor‐modified T cells in children and young adults with B‐acute lymphoblastic leukaemia	16
Posters	16
Evidence creation for myelofibrosis: Challenges and opportunities	16
Rounding off our Global View series	16
A single‐institution pre–post comparison of subcutaneous immunoglobulin replacement therapy in allogeneic haematopoietic cell transplantation recipients	16
Clinical outcomes and immune responses to SARS‐CoV‐2 vaccination in severe aplastic anaemia	16
Delayed haemolytic transfusion reaction in paediatric patients with sickle cell disease: A retrospective study in a French national reference centre	16
Issue Information	16
Integrative epigenomics in chronic lymphocytic leukaemia: Biological insights and clinical applications	15
Functional impairment of erythropoiesis in Congenital Dyserythropoietic Anaemia type I arises at the progenitor level	15
Machine/deep learning‐assisted hemoglobin level prediction using palpebral conjunctival images	15
	15
Ras‐associated autoimmune lymphoproliferative disorder	15
Digging into the HLA pockets: A new association with acute leukaemias	15
Don't forget cord blood in non‐remission acute myeloid leukaemia!	15

VANDA regimen followed by blinatumomab leads to favourable outcome in patients with Philadelphia chromosome‐negative B‐precursor acute lymphoblastic leukaemia in first relapse	15
Clinical utility of investigations in triple‐negative thrombocytosis: A real‐world, multicentre evaluation of UK practice	15
Favourable outcomes of double‐hit/double‐expressor lymphoma and high‐grade B‐cell lymphoma, not otherwise specified after early dose‐intensive treatment and up‐front autologous stem cell transplantati	15
Circulating monocytes phagocytosing lymphocytes in anaerobic infection	15
Persistent albuminuria and chronic kidney disease in adults with sickle cell anaemia: Results from a multicenter natural history study	15
Diagnosis and initial treatment of transplant‐eligible high‐risk myeloma patients: A British Society for Haematology/UK Myeloma Society Good Practice Paper	15
COVID‐19 infection in primary central nervous system lymphoma treatment: Who is most at risk?	15
Leukaemic blasts in a urine specimen in acute myeloid leukaemia with CEBPA mutation	15
CXCR4 antagonists disrupt leukaemia‐meningeal cell adhesion and attenuate chemoresistance	15
Low incidence of hyperacute graft‐versus‐host disease (GVHD) with effective GVHD prophylaxis based on anti‐thymocyte globulin	15
Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation‐ineligible relapsed and refractory diffuse large B‐cell lymphoma	15
Auer rod‐like inclusions in cerebrospinal fluid in accelerated phase chronic lymphocytic leukaemia	15
Higher than normal mitochondrial DNA content associated with better outcome in acute promyelocytic leukaemia? Maybe	15
Clinical features of primary vitreoretinal lymphoma developing extra‐central nervous system (CNS)/testicular lymphomas with or without CNS involvement: A single‐centre study of 1	15
Reduction in seroprevalence of viral transfusion‐transmitted infections in southwest Nigeria in children with sickle cell disease using an enhanced screening strategy	15
BCR::ABL1 transcripts and clinical outcome ‐ interrogating the technique	14
A real‐world study of immune thrombocytopenia management during the COVID‐19 pandemic in the UK	14
Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients	14
Liquid biopsy in Hodgkin lymphoma – moving beyond the proof of principle	14
Phase Ib study of eltrombopag and azacitidine in patients with high‐risk myelodysplastic syndromes and related disorders (the ELASTIC study)	14
Would you like to take some more ruxolitinib after your fedratinib?	14
Whole‐blood CCR7 expression and chemoattraction in red blood cell alloimmunization	14
In vitro anti‐lymphoma activity of the first‐in‐class pan‐NOTCH transcription inhibitor CB‐103	14
	14
	14
Population‐based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large‐cell lymphoma using Public Health England data	14
False‐positive heparin‐PF4 latex immunoturbidimetric assay due to lupus anti‐coagulant interference: a case report	14
Humoral and cellular responses to SARS‐CoV‐2 in patients with B‐cell haematological malignancies improve with successive vaccination	14
Computational analysis of a microRNA signature for poor prognosis suggests a microRNA‐controlled stemness pathway in paediatric acute leukaemia	14
Non‐myeloablative human leukocyte antigen‐matched related donor transplantation in sickle cell disease: outcomes from three independent centres	14
Rolling the DICEP on lymphoma salvage treatments? Choose wisely	14
Non‐pharmacological supportive‐care interventions in acute myeloid leukaemia: a review of randomised controlled trials	14
IGJ and SPATS2L immunohistochemistry sensitively and specifically identify BCR::ABL1+ and BCR::ABL1‐like B‐acute lymphoblastic leukaemia	14
Issue Information	14
Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti‐leukaemic potential and alloreactivity across major human leukoc	14
Lenalidomide maintenance following high‐dose therapy and autologous haematopoietic stem cell transplantation in chemo‐resistant or high‐risk non‐Hodgkin lymphoma: A phase I/II st	14
Does eventually NPM1 mutation in blast phase chronic myeloid leukemia (BP‐CML) exist? That is the question.	13
Therapy for isocitrate dehydrogenase 2 (IDH2)R172‐mutant acute myeloid leukaemia	13
Feasibility for non‐invasive prenatal fetal blood group and platelet genotyping by massively parallel sequencing: A single test system for multiple atypical red cell, platelet and quality control mark	13
Refractory immune thrombocytopenia in adults: Towards a new definition	13
T cell immune profiling of respiratory syncytial virus for the development of a targeted immunotherapy	13
Cost‐effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola‐R‐CHP) in previously untreated diffuse large B‐cell lymphoma in Germany	13
Gynaecological and reproductive health of women with telomere biology disorders	13
Sequential loss of B‐cell target antigens in multiply relapsed high‐grade B‐cell lymphoma treated with targeted therapies	13
Combined haploidentical and cord blood transplantation for refractory severe aplastic anaemia and hypoplastic myelodysplastic syndrome	13
New findings and new methods on macrophages in primary immune thrombocytopenia	13
Needs assessment in adults and parents of children living with sickle cell disease in Jamaica	13
Clover leaf nuclear morphology in chronic lymphocytic leukaemia with typical immunophenotype and absence of trisomy 12	13
POU6F2, a novel fusion partner of NUP98 in acute myeloid leukaemia: A case report	13
Distinct bone marrow immunophenotypic features define the splicing factor 3B subunit 1 (SF3B1)‐mutant myelodysplastic syndromes subtype	13
	13
Therapeutic plasma exchange in severe refractory autoimmune heparin‐induced thrombocytopenia with thrombosis	13
Erythrophagocytosis in a patient with myelodysplastic syndrome with excess blasts‐1 with isolated del(6q)	13
Using the in vitro drug sensitivity test to identify candidate treatments for transient abnormal myelopoiesis	13
Caplacizumab: A game changer also in pregnancy‐associated immune‐mediated thrombotic thrombocytopenic purpura?	13
Von Willebrand factor assays in patients with acquired immune thrombotic thrombocytopenia purpura treated with caplacizumab	13
The (near) miracle of therapy in chronic myeloid leukaemia	13
Methyl‐CpG binding domain 4, DNA glycosylase (MBD4)‐associated neoplasia syndrome associated with a homozygous missense variant in MBD4: Expansion of an emerging phenotype	13
Quality of life in childhood immune thrombocytopenia: Revision of the Kids' ITP Tools (KIT)	13
Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma	13
Cause of death and excess mortality in patients with lower‐risk myelodysplastic syndromes (MDS): A report from the European MDS registry	13
Issue Information	13
Recurrent mutations in multiple components of the SWI/SNF complex in myelodysplastic syndromes and acute myeloid leukaemia	13
Orals	13
Common‐sense combination therapy in refractory immune thrombocytopaenia	13
Dose reductions in immunoglobulin replacement are associated with increased antibiotic usage in patients with antibody deficiency	13
Use of dipyridamole is associated with lower risk of lymphoid neoplasms: a propensity score‐matched cohort study	12
e‐Posters	12
The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma XI’, a multicentre, open‐label, randomised, phas	12
Severe neonatal haemolytic anaemia caused by compound heterozygous KLF1 mutations: report of four families and literature review	12
Myelodysplastic syndrome associated‐haemophagocytic lymphohistiocytosis: A retrospective study of 15 cases in a single centre	12
Dual antiviral therapy in haematological patients with protracted SARS‐CoV‐2 infection	12
Induction of robust humoral immunity against SARS‐CoV‐2 after vaccine administration in previously infected haematological cancer patients	12
A Case of Postural‐Induced Peri‐Orbital Petechiae	12
Applying current smouldering myeloma risk models to a UK single‐centre cohort and clinical features at progression	12
Whole‐exome sequencing uncovered genetic diagnosis of severe inherited haemolytic anaemia: Correlation with clinical phenotypes	12
Distinct karyotypic and mutational landscape in trisomy AML	12
Author Index	12
Limited value of the D‐dimer based YEARS algorithm to rule out pulmonary embolism in sickle cell disease and sickle cell trait	12
Biomarkers of clinical severity in treated and untreated sickle cell disease: a comparison by genotypes of a single center cohort and African Americans in the NHANES study	12
HTLV‐1 and blood donation	12
Haematopoietic stem cell transplantation for hepatitis‐associated aplastic anaemia and non‐hepatitis‐associated aplastic anaemia: A propensity score‐matched analysis	12
Leukaemic transformation in a 10‐year‐old girl with SRP54 congenital neutropenia	12
Safety and efficacy of induction immunochemotherapy with rituximab, methotrexate, ifosfamide, and vincristine (R‐MIV) in patients with primary CNS lymphoma including recent	12
Antibiotic use in adults during sickle cell vaso‐occlusive crisis: Is it time for a controlled trial?	12
Qualitative study to support the content validity of the immune thrombocytopenia (ITP) Life Quality Index (ILQI)	12
Guideline development for prevention of transfusion‐associated graft‐versus‐host disease: reduction of indications for irradiated blood components after prestorage leukodepletion of blood compo	12
Classical and non‐classical phenotypes of Erdheim–Chester disease: Correlating clinical, radiographic and genotypic findings	12
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia	12
Promoter‐centred chromatin interactions associated with EVI1 expression in EVI1+3q− myeloid leukaemia cells	12
Identification of the minimum requirements for successful haematopoietic stem cell transplantation	12
COVID‐19 in patients with paroxysmal nocturnal haemoglobinuria: an Italian multicentre survey	12
Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L‐ASP: A retrospective analysis with an ASP‐based protocol in adult patients with acute lympho	12
Accessory spleens recapitulate the immune microenvironment of the main spleen in immune thrombocytopenia	12
The power and perils of large language models in haematology	11